Related Experiment Video
Updated: Apr 23, 2026
07:55
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
Published on: April 11, 2018
13.7K
Relative mortality in soft tissue sarcoma patients: a Danish population-based cohort study.
Katja Maretty-Nielsen1, Ninna Aggerholm-Pedersen, Johnny Keller
1Sarcoma Centre of Aarhus University Hospital, Aarhus, Denmark. k.maretty@dadlnet.dk.
BMC Cancer
|September 21, 2014
Summary
Relative mortality in soft tissue sarcoma (STS) patients is higher than the general population, especially within 5 years. However, cancer-specific mortality estimates may not differ significantly from relative mortality when death certificate data is high quality.
Area of Science:
- Oncology
- Epidemiology
- Biostatistics
Background:
- Accurate cancer survival estimates depend on precise cause-of-death data, which is challenging, especially in elderly patients with comorbidities.
- Relative mortality, comparing patient mortality to the general population, offers a more precise assessment than cancer-specific mortality alone.
- This study aimed to describe relative mortality in soft tissue sarcoma (STS) and compare it with cancer-specific mortality.
Purpose of the Study:
- To quantify and describe the relative mortality associated with soft tissue sarcoma (STS).
- To compare the relative mortality of STS patients with their cancer-specific mortality.
- To evaluate the accuracy of cancer-specific mortality estimates versus relative mortality.
Main Methods:
- A cohort of 1246 soft tissue sarcoma (STS) patients was compared to 6230 age- and sex-matched individuals from the general population.
- Relative mortality was calculated using rate ratios adjusted for comorbidity via Cox proportional hazard models for 0-5 and 5-10 year periods.
- Cancer-specific mortality data was compared against the calculated relative mortality.
Main Results:
- Overall 5- and 10-year relative mortality for STS patients was 32.8% and 36.0%, respectively.
- STS patients faced a 4.4 times higher risk of death within 5 years and 1.6 times higher risk between 5-10 years compared to the general population.
- Relative mortality varied by age, grade, stage, and comorbidity, with higher risks in younger, non-comorbid patients. Cancer-specific mortality slightly underestimated and then overestimated relative mortality.
Conclusions:
- Relative mortality is an unbiased and accurate method for distinguishing cancer-specific from non-cancer-specific deaths.
- When death certificate data quality is sufficient, relative mortality and disease-specific mortality show no significant difference.
- The findings highlight the importance of considering relative mortality for a comprehensive understanding of STS impact.
Related Concept Videos
01:03Rous Sarcoma Virus (RSV) and Cancer
5.2K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.2K
01:21Cancer Survival Analysis
857
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
857